DEA to publish 4th extension of telehealth prescribing rule in wave of relief for virtual care providers - Fierce Healthcare
DEA extends telehealth prescribing flexibilities for controlled substances for the fourth time, providing continued relief for virtual care providers.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: Extension effective immediately; final rule expected by end of 2024.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA extends the temporary rule allowing telehealth prescribing of controlled substances without an in-person visit, effective until the end of 2024 or until a permanent rule is finalized.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies
What you must do
Continue to comply with existing telehealth prescribing requirements under the current extension; monitor for final rule.
Deadline
Extension effective immediately; final rule expected by end of 2024.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order